A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by M
- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol
- Data presented at European Atherosclerosis Society 92nd Congress.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report)’s stock price dropped 2.6% on Tuesday . The stock traded as low as $24.24 and last traded at $24.24. Approximately 37,306 shares changed hands during trading, a decline of 97% from the average daily volume of 1,348,370 shares. The stock had previously closed at $24.88. Analyst Ratings […]
Phase 2b study results show that investigational plozasiran significantly reduced triglyceride-rich lipoproteins in patients with mixed hyperlipidemia.
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.